April 1, 2019
Turning Point Therapeutics’ Kinase Inhibitors Show High Potency against Targeted Oncogene Drivers and Their Mutations
Company Presents Four Studies at American Association for Cancer Research (AACR) Annual Conference Preclinical Data for Lead Asset Repotrectinib Continue…